EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSCHAG00000003013
Gene Symbol: KCNJ3
3 Cross references
150 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSCHAG00000026736
Gene Symbol: KCNJ3
3 Cross references
221 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSCHAG00000008999
Gene Symbol: KCNJ5
3 Cross references
209 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSCHAG00000023446
Gene Symbol: KCNK2
3 Cross references
221 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSCHAG00000027402
Gene Symbol: KCNA5
3 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSCHAG00000006548
Gene Symbol: KCND3
1 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSCHAG00000017506
Gene Symbol: KCNH2
1 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSCHAG00000024632
Gene Symbol: KCNQ2
1 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSCHAG00000027745
Gene Symbol: KCNQ5
1 Cross references
200 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSCHAG00000001903
Gene Symbol: KCNQ2A
1 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSCHAG00000000783
Gene Symbol: KCND3
1 Cross references
194 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSCHAG00000019592
Gene Symbol: KCNH2A
1 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).